“We're basically not using our body as directed,” says "Drug Story" host Thomas Goetz.
Nancy Cox, a CDC veteran who for decades was a global leader in influenza research, has died at 77.
“We're basically not using our body as directed,” says "Drug Story" host Thomas Goetz.
Trump's embrace of psychedelics and cannabis is shaking up the GOP’s relationship with mind-altering substances.
What did Eli Lilly see in a struggling biotech startup that made the pharma giant want to pay billions for it? Bryan Roberts has some answers.
A Utah pilot to renew prescriptions using a bot faced backlash from the state's medical board, which called for an immediate suspension.
From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.
In today's Morning Rounds newsletter, a new era in GOP drug policy, an international childhood vaccine campaign grows, and more.
President Trump heralded a drug-pricing agreement with Regeneron, closing the last of 17 deals sought by the White House
A multiple sclerosis drug from Sanofi that was rejected late last year by the FDA found a warmer reception in Europe.
Starting residency at 72 isn’t for the faint of heart. But that’s what Dawn Zuidegeest-Craft is doing.
Health and science reporting is often treated as optional coverage. It is anything but.
The problematic use of guest editors was spotlighted last week when a genetics journal retracted nearly an entire special issue.
In this week’s STATus Report, host Alex Hogan chats with STAT Washington correspondent Daniel Payne about Trump's psychedelics EO.
A newly confirmed mass grave in ancient Jordan offers chilling insight into one of history’s first pandemics. Hundreds of plague victims were buried within days, revealing how the Plague of Justinian devastated entire communities. The findings show that people who usually lived spread out across regions were suddenly concentrated in death. It’s a powerful reminder that pandemics don’t just spread disease—they reshape how societies live and collapse.
This week on "The Readout LOUD": a CAR-T biotech's dramatic turnaround, and drugmakers' tactics to drive more scripts. Listen now.
A deal with Regeneron was the last of 17 initially sought by the White House.
The constant pressure that the heart is under from beating thousands of times a day may create an environment hostile to cancers
The Trump administration, in a stark departure from the "Just Say No" era, is funding psychedelics research and rescheduling marijuana.
Legislators in two states are resisting efforts to restrict prescription drug affordability boards.
Since the 1918 pandemic, the military has acknowledged the threat of influenza. Now that’s changing.
A gene therapy for deafness, all eyes on Erasca, and other biotech news from The Readout
Federal regulators are proposing a new, faster Medicare coverage pathway for medical devices deemed by the FDA as breakthroughs.
RFK Jr. is backing vaccinations and defending secret deals with pharma companies.
In this edition of STAT Health Tech: OpenAI's targets clinicians, AMA's call for regulatory crackdown, and bargain-basement telehealth visits.
President Trump is reclassifying state-licensed medical marijuana as a less-dangerous drug, a major policy shift long sought by advocates.
Drugmakers have begun using coupons to discount the cost of telehealth visits with clinicians who can prescribe their drugs
Discount telehealth visits, maternal mortality data, and more health news from Morning Rounds
A rare group of adults over 80, known as SuperAgers, are rewriting what we thought was possible for the aging brain. With memory abilities comparable to people decades younger, their brains either resist or withstand the damage typically linked to Alzheimer’s disease. Decades of research reveal that their social lifestyles and unique brain biology may hold the key to preserving cognitive function. Scientists believe these insights could pave the way for new strategies to delay or even prevent dementia.
Can Erasca be biotech's next big thing?
Scientists have identified two specific types of brain cells that behave differently in people with depression, offering a clearer picture of what is happening inside the brain. By analyzing donated brain tissue with advanced genetic tools, the researchers found changes in neurons linked to mood and stress, as well as in immune-related microglia cells. These differences point to disruptions in key brain systems and reinforce that depression is rooted in biology, not just emotions.
Kennedy’s public messaging on vaccines has shifted ahead of the midterms. It won’t last.
As links between pharmaceutical companies and telehealth providers grow, health policy experts and legislators have sounded alarms.
A new minimally invasive procedure may help people keep weight off after stopping popular drugs like Ozempic and semaglutide—something most patients struggle with. In a clinical trial, those who underwent a technique called duodenal mucosal resurfacing regained far less weight compared to others after discontinuing the medication. The procedure works by renewing the lining of the upper small intestine, potentially “resetting” metabolism and preserving the benefits of weight loss.
Kennedy continues to make waves across health care, but he's pulled back on a number of core MAHA issues.
A new Medicare prior authorization test is delaying care at Washington state hospitals – and should be scrapped, senator says.
Naming a former Imperial Brands executive for a CDC job is the latest example, advocates say, of tobacco industry influence in Trump administration.
At AACR, there was talk of Chinese biotech's place in cancer research, oncology’s comms issue, and more.
Watch RFK Jr. testify before the Senate's health care panel.
Suicide rates among young people dropped 11% after the U.S. launched the 988 national suicide and crisis hotline, a new study shows
After gene therapy for a rare form of deafness, 90% of participants in a clinical trial in China had significant improvement in hearing.
Try another keyword or clear the search box.